The results demonstrated:

• After 60 min following the administration of MS, decrease in the intensity of pain was observed. Severe pain was found to be reduced by 54.1% whereas 16.1% reduction was observed in moderate pain
• In addition, systolic arterial pressure (SAP) declined by 35.7 mmHg while 16.8 mmHg reduction was seen in diastolic arterial pressure (DAP)
• The heart rate (HR) also diminished by 25.1 beats/min
• After 90 and 180 min following the intake of MS, 21.8% and 25.3% of the patients showed positive dynamics of ST segment, respectively
• Furthermore, the height of the ST segment was found to be normal in 18.4 and 31.0% of the patients, respectively
• No evidence of death was reported from heart rupture by MS therapy in comparison to 39.1% of the patients who received standard thrombolytic therapy.

"MS therapy is effective in the management of pre-hospital stage in patients with acute coronary syndrome"